Assyro AI

FDA Orange Book · active-ingredient family

Avacincaptad pegol sodium

Avacincaptad pegol sodium is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:IZERVAY · NDA 217225

1

Brand (NDA)

0

Generics (ANDA)

6

Listed patents

0

Exclusivity periods

Brand (NDA) products · solution

ProductApplicantApplicationTEApproved
IZERVAYRLDASTELLASNDA 217225—Aug 04, 2023

Listed patents (6)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8236773Nov 11, 2026in 5 mo
U-3673
9617546Feb 14, 2027in 8 mo
SubstanceU-3673
7579456Feb 14, 2027in 8 mo
Substance
11491176Jul 11, 2034in 8 yr 2 mo
U-3673
11273171Jul 11, 2034in 8 yr 2 mo
U-3673
12016875Jul 11, 2034in 8 yr 2 mo
U-3673

Avacincaptad pegol sodium — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo